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Trypanosoma cruzi, the causative agent of Chagas 
disease, infects more than 11 million people and kills 
an estimated 50,000 individuals annually (CDC 2007). 
Up to 30% of infected individuals will develop compli-
cations from Chagas disease, which include cardiomyo-
pathy and the mega-syndromes (megaesophagus and 
megacolon). In humans, natural infection occurs primar-
ily through contact with T. cruzi-contaminated reduviid 
excreta, usually through breaks in the skin or mucosal 
surfaces. Recent reports of large-scale outbreaks follow-
ing food or drink contamination demonstrate the dan-
gers of oral T. cruzi infection (Dias et al. 2008, Beltrão et 
al. 2009, Nóbrega et al. 2009, Pereira et al. 2009, Alarcón 
de Noya et al. 2010). 
Because parasite proteins are expressed differen-
tially in distinct T. cruzi life stages, it may be difficult 
to develop a vaccine that establishes sterile immunity. 
Glycoprotein-82 (gp82), a stage-specific protein present 
on the surface of T. cruzi metacyclic trypomastigotes 
(MT), has been shown to bind to gastric mucin and to 
facilitate the Ca2+-signaling activity necessary for para-
site internalization (Yoshida 2006, 2009). Isolates of T. 
cruzi that lack gp82 expression are much less efficient at 
infecting mice orally than those that express high levels 
of gp82 (Cortez et al. 2003). Antibodies that bind to gp82 
inhibit the in vitro infection of epithelial cells (Neira 
et al. 2003). Although gp82 is only expressed by MT, 
it could be a good target for immune responses aimed 
at providing protection against initial immune invasion 
and intracellular replication cycles. 
It is well documented that type 1 immune respons-
es are critical for protection against both mucosal and 
systemic T. cruzi infection (Hoft et al. 2000, Hoft & 
Eickhoff 2005, Rodrigues et al. 2009). The CpG motifs 
present within ssDNA are known to induce type 1 im-
mune responses mediated by toll-like receptor 9 (TLR9) 
stimulation and have been used as adjuvants safely and 
effectively in mice and humans (Krieg 2000, Dumais et 
al. 2002, Cooper et al. 2005). Several independent groups 
have shown the induction of protective immune respons-
es against lethal T. cruzi challenge using CpG mixed with 
whole T. cruzi lysate or various recombinant T. cruzi pro-
teins (Frank et al. 2003, Araújo et al. 2005, Hoft et al. 
2007). In this study, we tested a mucosal T. cruzi vac-
cine containing the gp82 protein. We show that intranasal 
vaccination with CpG + gp82 induces protective immune 
responses against mucosal T. cruzi challenge. 
MATERIALS AND METHODS
Parasites and mice - Female Harlan Sprague Dawley 
BALB/c mice aged 6-8 weeks were used throughout these 
studies and housed in Association for Assessment and 
Accreditation of Laboratory Animal Care International 
(AAALAC) accredited facilities. Tulahuén strain T. cruzi 
insect-derived MT (IMT), culture-derived MT and blood 
form trypomastigotes (BFT) were prepared as previously 
described (Hoft & Eickhoff 2005, Giddings et al. 2006). 
Opsonization and T. cruzi challenges - IMT mixed 
1:1 with 0.5 mg/mL MAb-3F6 (gp82-specific monoclo-
nal antibody) or isotype control (Sigma, St. Louis, MO, 
USA) were incubated at RT for 30 min prior to conjunc-
tival or oral challenges, which were performed as previ-
ously described (Hoft 1996, Giddings et al. 2006). 
Immunization with CpG-gp82 - Recombinant gp82 
and control glutathione S-transferase (GST) proteins were 
prepared as previously described (Santori et al. 1996). Oli-
godeoxynucleotide (ODN) # 1826 (5’-TCCATGACGTTC-
CTGACGTT-3’) containing CpG motifs (underlined) and 
control ODN were purchased from Coley Pharmaceuticals 
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(Wellesley, MA). BALB/c mice were immunized intrana-
sally twice, two weeks apart, using 10 µg CpG 1826 mixed 
with 2-10 µg gp82 (or control GST).
Measurement of vaccine induced immunity - Four 
weeks after immunization, spleen cells from vaccinated 
mice were stimulated at 1 x 106 cells/mL in round-bottom 
96-well plates with 0.4-2.0 µg/mL recombinant gp82 
or control GST protein. Spleen cells (4 x 106/mL) from 
these same immunized mice were stimulated in 24-well 
plates with medium or 10 µg/mL T. cruzi lysate (Hoft 
& Eickhoff 2005). Three days later, proliferation and 
IFN-γ secretion were assessed as previously described 
(Hoft & Eickhoff 2005). 
Determination of parasite infectivity - Four weeks 
after the final immunization, some mice (n = 5/group) 
were challenged with 5,000 BFT subcutaneously and 
survival was monitored as a means of analyzing system-
ic protective immunity. Other groups of mice (n = 5-8/
group) were challenged orally with 1,000 IMT and para-
site replication in mucosal tissues was determined using 
T. cruzi-specific real-time polymerase chain reaction 
(PCR). Mice were harvested 11-13 days after mucosal T. 
cruzi challenge and the levels of parasite replication were 
measured in draining lymph node and tissue DNA sam-
ples using T. cruzi-specific real-time PCR as previously 
described (Giddings et al. 2006, Hoft et al. 2007). Brief-
ly, DNA was purified from splenic and gastric lymph 
node tissue (after oral MT challenge) and from subman-
dibular lymph nodes (after conjunctival MT challenge) 
using a commercially available kit (DNeasy, QIAGEN). 
T. cruzi-specific real-time PCR was performed using 
100 ng of purified DNA per reaction.
Ethics - All animal studies were performed in 
AAALAC accredited facilities (NIH Assurance A3225-
01). In addition, all mouse studies were approved by the 
Institutional Animal Care and Use Committee/Animal 
Care Committee at Saint Louis University.
RESULTS
Gp82-specific antibodies reduce T. cruzi infectiv-
ity - Our group has shown that the opsonization of T. 
cruzi MT with faecal extracts containing T. cruzi-spe-
cific secretory IgA can reduce parasite infectivity after 
conjunctival challenge (Giddings et al. 2006). In the 
present study, we incubated Tulahuén strain IMT with a 
control or gp82-specific MAb-3F6. The opsonized para-
sites were then placed on the conjunctiva of anesthetized 
mice or fed orally to naïve mice. Two weeks later, mice 
were sacrificed and parasite replication was determined 
by real-time PCR in tissues taken from sites of early 
infection. In mice challenged conjunctivally with anti-
gp82-opsonized parasites, significantly reduced parasite 
DNA was detectible in the lymph nodes that drain the 
site of initial invasion in the nasal cavity relative to mice 
infected with control opsonized parasites (p < 0.04 by 
Mann-Whitney U test) (Fig. 1A).
Similarly, mice challenged orally with anti-gp82-op-
sonized parasites had ~4-fold lower amounts of T. cruzi 
DNA recoverable at the site of initial invasion in gastric 
tissue compared with controls (Fig. 1B). These results 
Fig. 1: decreased parasite infectivity after opsonization with glycopro-
tein-82 (gp82)-specific antibodies. Insect-derived metacyclic trypo-
mastigotes (IMT) were incubated with control or anti-gp82 specific 
monoclonal antibodies and then either placed on the conjunctiva of 
anesthetized mice (A) or fed orally to BALB/c mice (B, C). DNA ex-
tracted 11-13 days later from local draining tissues (parotid and sub-
mandibular lymph nodes (LN) from conjunctivally challenged mice or 
gastric DNA from orally challenged animals) or distant sites (spleen) 
were used in Trypanosoma cruzi specific real-time polymerase chain 
reaction assays. In panel A, the numbers of T. cruzi molecular equiva-
lents (ME) per 100 ng of DNA is significantly lower (asterisk means 
p < 0.04 by Mann-Whitney U test) in anti-gp82 opsonized MT-infected 
mice than in control opsonized MT-infected mice. Similarly, mice chal-
lenged orally had markedly reduced amounts of T. cruzi DNA present 
in gastric samples after opsonization with anti-gp82 monoclonal an-
tibody (MAb)-3F6 as compared to controls (B). In addition, systemic 
spread of parasites was inhibited by opsonization with anti-gp82, as 
seen in panel C where reduced parasite DNA was detectable in spleens 
recovered from mice that were infected with anti-gp82 MAb 3F6-
opsonized MT compared with control opsonized MT (asterisk means 
p < 0.02 Mann-Whitney U Test). NC: negative control.
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show that gp82-specific antibodies can reduce infectivity 
at the initial sites of parasite mucosal invasion after both 
conjunctival and oral T. cruzi challenges. In addition, sig-
nificantly decreased amounts of parasite DNA were de-
tected in splenic DNA samples isolated from mice chal-
lenged orally with anti-gp82 opsonized MT compared with 
mice challenged with control opsonized MT (p < 0.02 by 
Mann-Whitney U test) (Fig. 1C). Thus, the systemic spread 
of parasite infection can be curtailed by opsonization with 
gp82-specific antibody, suggesting that disseminated dis-
ease from T. cruzi can be limited by the neutralization of 
initial parasite infectivity. 
Intranasal vaccination with CpG-gp82 induces T. cru-
zi-specific type 1 immune responses - Systemic immuniza-
tion with alum + gp82 has previously been shown to induce 
immune responses that were capable of reducing parasi-
taemia after systemic MT challenge (Santori et al. 1996). 
In the present study, we intranazally vaccinated mice with 
gp82 adjuvanted with CpG, a TLR-9 agonist. Four weeks 
following the second and final immunization, spleen cells 
from immunized animals were harvested and stimulated 
with antigen. The spleen cells from mice immunized with 
CpG-gp82 proliferated in a dose-dependant manner in re-
sponse to recombinant gp82 antigen stimulation in vitro 
(Fig. 2A). Spleen cells from these same vaccinated animals 
produced IFN-γ upon in vitro stimulation with gp82 (Fig. 
2B). Additionally, spleen cells from mice immunized with 
CpG-gp82 produced IFN-γ after in vitro stimulation with 
whole T. cruzi lysate (Fig. 2C). The production of IFN-γ 
by spleen cells from gp82-immunized mice after stimula-
tion with T. cruzi antigens is especially important because 
type 1 immune responses have been shown to be critical in 
protecting against both systemic and mucosal T. cruzi chal-
lenges (Hoft & Eickhoff 2002, 2005). 
Intranasal CpG-gp82 isimmunization fails to protect 
mice against systemic BFT challenge - In order to assess 
protective immunity induced by CpG-gp82 immuniza-
tion, immunized mice were challenged systemically or 
mucosally four weeks after their second and final vaccina-
tion. For systemic survival studies, 5,000 BFT diluted in 
100 µL PBS were injected subcutaneously at the base of 
the tail. As seen in Fig. 3A, mice immunized with CpG-
gp82 failed to survive lethal T. cruzi challenge and time to 
death was not prolonged. 
CpG-gp82 immunization results in protection after 
a biologically relevant mucosal MT challenge - In order 
to study mucosal protection, immunized mice were chal-
lenged orally with 1,000 IMT. DNA was extracted from 
stomachs 11-13 days after oral challenge and infection levels 
were measured using T. cruzi-specific real-time PCR. The 
gastric DNA obtained from CpG-gp82-vaccinated mice 
contained significantly reduced amounts of T. cruzi DNA 
compared with gastric DNA samples from CpG-negative 
control GST-immunized mice (p < 0.05 by Mann-Whitney 
U test) (Fig. 3B).
DISCUSSION
All four T. cruzi life stages have been studied for gp82 
expression by simple IFA, Western blot and, more recently, 
by proteome analysis (Teixeira & Yoshida 1986, Atwood 
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Fig. 2: type 1 mediated immune responses induced by intranasal CpG-
glycoprotein-82 (gp82) immunization. BALB/c mice were immunized 
twice two weeks apart with 10 µg CpG 1826 mixed with 2.5-10 µg 
gp82 or control glutathione-S-transferase (GST) protein. Four weeks 
later, spleen cells were removed and stimulated in vitro for three 
days with control protein, recombinant gp82, or Trypanosoma cruzi 
lysate, after which time proliferative responses were detected using 
3H-thymidine incorporation and IFN-γ secretion measured via ELISA. 
Negative control stimulation values were subtracted. Spleen cells from 
mice immunized with CpG-gp82 proliferated and produced IFN-γ in 
a dose dependent manner in response to recombinant gp82 stimulation 
in vitro (A, B). As seen in panel C, mice immunized with CpG-gp82 
also produced IFN-γ in response to T. cruzi lysate stimulation. Based 
on these immune response results, 10 µg gp82 was chosen for immuni-
zation and challenge experiments to assess vaccine-induced protective 
immunity DPM: disintegrations per minute; NC: negative control.
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et al. 2005, CDC 2007, The T. cruzi proteome database 
2007). It is clear that gp82 is only expressed by T. cruzi 
MT and not by T. cruzi intracellular amastigotes (AMA) or 
BFT. The critical role of gp82 in parasite mucosal epitheli-
al invasion makes this T. cruzi glycoprotein an ideal target 
for mucosal immune responses. It is a highly conserved 
molecule present in nearly all T. cruzi isolates, including 
strains Y, CL, F, Tulahuén, G and others (Yoshida 2006). 
Epimastigotes do not express gp82 and are non-infectious 
(Manque et al. 2003). In addition, gp82-deficient MT are 
defective in mucosal infectivity in mice after oral delivery 
(Cortez et al. 2003). The binding of gp82 to gastric mu-
cin induces intracellular Ca+ increases dependent on ATP 
consumption, an increase which appears to be required 
for parasite internalization. The interaction and binding 
of gp82 to gastric mucin may explain earlier findings in 
which MT, but not BFT, efficiently infected mice after oral 
challenge (Hoft 1996). Previous work has shown that anti-
bodies directed against gp82 significantly reduce parasite 
infectivity both in vitro and after oral in vivo challenges. 
We have extended these findings by (i) showing that anti-
gp82 Abs can block T. cruzi infection via both conjuncti-
val and oral routes and (ii) demonstrating that a mucosal 
vaccine can significantly reduce mucosal infection after 
oral T. cruzi challenge. It seems likely that the gp82 gas-
tric mucin-binding epitope overlaps with the gp82-specific 
MAb-3F6 epitope. Alternatively, immune responses di-
rected against gp82 could block the induction of Ca+/ATP-
mediated membrane repair responses, thereby preventing 
active parasite internalization. 
It has been reported that mice challenged systemi-
cally with MT after gp82 vaccination develop lower 
parasitaemia compared with control immunized mice 
(Santori et al. 1996). However, those data were gener-
ated using an MT challenge as opposed to a BFT chal-
lenge and the endpoint analysis was peak parasitaemia 
rather than death. In our study, we found no evidence of 
protection against systemic BFT challenge. Stage-spe-
cific gp82 expression on MT (not AMA or BFT) is the 
most logical explanation for these apparently conflict-
ing data because immune responses directed towards 
MT may not be effective when BFT not expressing 
gp82 are used for parasite challenge. Because Santori et 
al. (1996) used an MT challenge, the gp82-specific im-
munity that was induced could have partially protected 
against this initial infecting stage. However, we chal-
lenged systemically with BFT that did not express gp82 
and, therefore, the gp82-specific immunity is likely to 
have been irrelevant in recognizing this infection. 
Many studies investigating T. cruzi vaccine develop-
ment have focused on the induction of systemic immune 
responses and have utilized lethal, but perhaps biologi-
cally irrelevant, challenge models. As new natural in-
fections in humans occur through contact with IMT-
contaminated reduviid excreta, we must investigate the 
effects of vaccine-induced immunity on these types of 
infections. Our results showing gp82 vaccine-induced 
mucosal protection after a biologically relevant IMT 
challenge are one such example of these types of stud-
ies. Future T. cruzi vaccines should encode antigens that 
can induce both mucosal and systemic immunity. The 
gp82 antigen could facilitate the induction of optimal 
mucosal protection, but other antigens will be required 
for the induction of optimal systemic protection.
The prevalence of human T. cruzi infection increas-
es dramatically with the presence of infected dogs in 
households (Cohen & Gürtler 2001). The removal of 
infected dog reservoirs alone can reduce the threat of 
human T. cruzi transmission. Previous studies on dogs 
immunized with live-attenuated T. cruzi epimastigotes 
provided partial protection against natural T. cruzi in-
fection (Basombrio et al. 1993). Currently, it may be 
more feasible to develop a vaccine aimed at prevent-
ing systemic and mucosal infection of domesticated 
animals rather than humans. Our data clearly show that 
immunization with gp82 induces significant mucosal 
protection and could be useful in vaccines designed to 
prevent mucosal infection in dogs. 
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Fig. 3: mucosal protective immunity induced by intranasal CpG-glyco-
protein-82 (gp82) immunization. BALB/c mice were immunized intra-
nasally twice two weeks apart with 10 µg CpG 1826 mixed with 10 µg 
gp82 or control glutathione-S-transferase protein. Four weeks after the 
final immunization, groups of mice were challenged with 5,000 blood 
form trypomastigotes (BFT) subcutaneously (A) or with 1,000 insect-
derived metacyclic trypomastigotes orally (B). Control and CpG-gp82 
immunized mice failed to survive challenge with a normally lethal dose 
of Trypanosoma cruzi BFT (A). However, as compared with the control 
immunized group, mice vaccinated with CpG-gp82 had significantly 
lower amounts of T. cruzi DNA detectable in gastric DNA samples tak-
en 12 days post infection as determined by T. cruzi specific real-time 
polymerase chain reaction (B) (asterisk means p < 0.01 using Mann-
Whitney U test). ME: molecular equivalente; NC: negative control.
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Other vaccines composed of T. cruzi proteins ex-
pressed by BFT and/or AMA (including TS and ASP-2) 
induce strong T-cell responses and systemic protection 
in mice (Fujimura et al. 2001, Araújo et al. 2005). A vac-
cine composed of several stage-specific proteins could 
perhaps lead to optimal protective immunity by induc-
ing immune responses that are relevant for both mucosal 
and systemic protection. Focusing future vaccine strat-
egies on domestic animals would be much safer than 
vaccinating humans and could interrupt transmission in 
households. Thus, a multi-component vaccine that in-
cludes gp82 and is aimed at preventing T. cruzi infection 
in dogs should be explored.
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